Correction to: Leukemia (2014) 28, 1774–1783; doi:10.1038/leu.2014.124
Since the publication of this article, the authors have identified an error within the following sentence (page 1780):
Finally, Metzeler et al.92 evaluated 46 elderly patients with AML treated with decitabine with or without the histone deacetylase inhibitor vorinostat, and found a significantly higher CR rate in patients with DNMT3A mutations (75%) versus wild-type DNMT3A (34%).
The correct sentence should read:
Finally, Metzeler et al.92 evaluated 46 elderly patients with AML treated with decitabine with or without the proteasome inhibitor bortezomib, and found a significantly higher CR rate in patients with DNMT3A mutations (75%) versus wild-type DNMT3A (34%).
The authors would like to apologise for any inconvenience this may have caused.
Additional information
The online version of the original article can be found at 10.1038/leu.2014.124
Rights and permissions
About this article
Cite this article
Im, A., Sehgal, A., Carroll, M. et al. Erratum: DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 29, 516 (2015). https://doi.org/10.1038/leu.2014.269
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.269
